Top

Published in:

01-04-2017 | Letter

PCSK9 inhibition and the global diabetes epidemic

Authors: Luca Mascitelli, Mark R. Goldstein

Published in: Diabetologia | Issue 4/2017

Excerpt

To the Editor: Preiss and Mafham [1] analysed the potential efficacy and safety of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors in reducing major cardiovascular events in clinical practice. However, the diabetogenic effect of PCSK9 inhibition was downplayed by the authors. …

Preiss D, Mafham M (2016) PCSK9 inhibition: the dawn of a new age in cholesterol lowering? Diabetologia. doi:10.1007/s00125-016-4178-y

Schmidt AF, Swerdlow DI, Holmes MV et al (2016) PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. Lancet Diabetes Endocrinol. doi:10.1016/S2213-8587(16)30396-5

Ference BA, Robinson JG, Brook RD et al (2016) Variation in PCSK9 and HMGCR and risk of cardiovascular disease and diabetes. N Engl J Med 375:2144–2153CrossRefPubMed

Williams RR, Hasstedt SJ, Wilson DE et al (1986) Evidence that men with familial hypercholesterolemia can avoid early coronary death. An analysis of 77 gene carriers in four Utah pedigrees. JAMA 255:219–224CrossRefPubMed

Sijbrands EJ, Westendorp RG, Defesche JC, de Meier PH, Smelt AH, Kastelein JJ (2001) Mortality over two centuries in large pedigree with familial hypercholesterolaemia: family tree mortality study. BMJ 322:1019–1023CrossRefPubMedPubMedCentral

Sidney S, Quesenberry CP Jr, Jaffe MG et al (2016) Recent trends in cardiovascular mortality in the United States and public health goals. JAMA Cardiol 1:594–599CrossRefPubMed

Title: PCSK9 inhibition and the global diabetes epidemic
Authors: Luca Mascitelli
Mark R. Goldstein
Publication date: 01-04-2017
Publisher: Springer Berlin Heidelberg
Published in: Diabetologia / Issue 4/2017
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI: https://doi.org/10.1007/s00125-017-4217-3

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

PCSK9 inhibition and the global diabetes epidemic

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2017

Targeted deletion of Traf2 allows immunosuppression-free islet allograft survival in mice

Targeted next-generation sequencing reveals MODY in up to 6.5% of antibody-negative diabetes cases listed in the Norwegian Childhood Diabetes Registry

Erratum to: Non-metabolisable insulin glargine does not promote breast cancer growth in a mouse model of type 2 diabetes

Enhanced VEGF signalling mediates cerebral neovascularisation via downregulation of guidance protein ROBO4 in a rat model of diabetes

Associations between hepatic miRNA expression, liver triacylglycerols and gut microbiota during metabolic adaptation to high-fat diet in mice

Re-addressing the 2013 consensus guidelines for the diagnosis of insulitis in human type 1 diabetes: is change necessary? Reply to Campbell-Thompson ML, Atkinson MA, Butler AE et al [letter]

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page